Designated Devices for AI treatment: Industry Perspective

Monday, February 27, 2023

3:39 PM – 3:47 PM ET

Speaker(s)

Duane Pinto, MD, MPH, FSCAI

Chief Medical Officer
JenaValve
Boston, Massachusetts, United States

Disclosure(s): Abbott Vascular, Asahi, Boston Scientific, St Jude, Terumo: Consulting fees or other remuneration (Ongoing); Abiomed: Consultant (Ongoing), University Grants/Research Support (Ongoing); Biotronik: Consultant (Ongoing); BSC: Consultant (Ongoing), University Grants/Research Support (Ongoing); CSL Behring: Consultant (Ongoing), University Grants/Research Support (Ongoing); JenaValve Technology Inc: Employee (Ongoing); Magenta Medical: Consultant (Ongoing); Medtronic Inc: Consultant (Ongoing); NuPulse CV, Inc.: Stock-privately held company (Ongoing)

Disclosure(s):

Duane Pinto, MD, MPH, FSCAI: Abbott Vascular, Asahi, Boston Scientific, St Jude, Terumo: Consulting fees or other remuneration (Ongoing); Abiomed: Consultant (Ongoing), University Grants/Research Support (Ongoing); Biotronik: Consultant (Ongoing); BSC: Consultant (Ongoing), University Grants/Research Support (Ongoing); CSL Behring: Consultant (Ongoing), University Grants/Research Support (Ongoing); JenaValve Technology Inc: Employee (Ongoing); Magenta Medical: Consultant (Ongoing); Medtronic Inc: Consultant (Ongoing); NuPulse CV, Inc.: Stock-privately held company (Ongoing)